Immune support

A smaller set of peptides is studied for immune modulation and host defense. The two documented here illustrate two very different positions on the evidence and regulatory spectrum.

Thymosin alpha-1 (Zadaxin) is a defined, manufactured immunomodulator that is approved and marketed in many countries (though not by the FDA or EMA) and has been studied as an adjunct in chronic hepatitis, sepsis, and cancer care. Its evidence is genuinely mixed by indication. A small positive sepsis trial, for example, was later not confirmed by a larger negative one, so it is best read as "approved abroad, with contested efficacy." LL-37 is the body's own cathelicidin antimicrobial peptide; it is studied for direct antimicrobial and immune-signalling roles, with limited early human data (mostly small topical wound-healing trials). LL-37 is also double-edged: it is implicated in autoimmune conditions (psoriasis, lupus, rosacea) and has context-dependent roles in cancer.

Conditions people ask about

Popular videos, clinic blogs, and high-claim content in this area promise to "reverse", "reset", or "cure" serious autoimmune and viral conditions with a peptide protocol. That framing is not supported: no compound on this site is an approved treatment for any condition below, and the dramatic reversal or remission claims that circulate lack controlled human evidence. These notes exist to answer what people actually search for honestly, not to guide treatment. Any of these conditions is a matter for a licensed clinician and a proper diagnosis — a research peptide is not a substitute.

Hashimoto's thyroiditis

The community frames Hashimoto's as autoimmune disease you can "calm", "reverse", or push into remission by lowering TPO antibodies with a thymic-peptide protocol, typically pairing a thymic peptide with a gut-repair peptide. In reality, no peptide is an approved treatment for Hashimoto's anywhere; the established, evidence-based therapy is clinician-managed levothyroxine replacement with proper antibody and thyroid-function testing. The autoimmune-thyroid data is preclinical and genuinely double-edged — in mice bred to make anti-thyroid antibodies, thymic peptide opposed experimental autoimmune thyroiditis, yet in autoimmunity-resistant mice it could itself trigger a mild thyroiditis (PMID 3873993) [Animal] — and the specific "TPO dropped 38%" figures on vendor sites trace to no identifiable controlled trial. Thymosin alpha-1 is an approved immune-modulating drug abroad (hepatitis B, immunodeficiency) but not for Hashimoto's and not FDA/EMA-approved, with animal-only, bidirectional thyroid data; Thymalin is a Russian-registered thymus-extract immunomodulator discussed for "immune balancing" on older, under-replicated work, and immune-stimulating thymic peptides are explicitly cautioned in active autoimmune disease; Thymogen is a synthetic dipeptide derived from thymalin, marketed as an immune modulator on small, under-replicated studies; BPC-157 is included in community "Hashimoto protocols" on a gut-healing rationale rather than a thyroid one, with human evidence absent for any indication. None has controlled human evidence for Hashimoto's. This condition needs a licensed clinician and a real diagnosis; a research peptide is not a substitute.

Lupus (SLE)

High-claim content presents thymic peptides as able to "rebalance" or "reset" the immune system in lupus by boosting regulatory T-cells, sometimes citing precise-sounding trial numbers (e.g. large SLEDAI drops) to imply a peptide can control the disease. In reality, no peptide is an approved treatment for systemic lupus erythematosus; SLE is managed by rheumatologists with approved immunosuppressants and biologics under close monitoring, and the specific patient counts and SLEDAI figures repeated on vendor pages do not map to any verifiable trial [Human]. Critically, one inventory peptide cuts the other way: cathelicidin LL-37 is implicated as a pathogenic autoantigen in lupus — LL-37/DNA complexes drive plasmacytoid dendritic cells to produce type-I interferon, a core lupus mechanism (PMC7388365) [Human/In vitro] — so "LL-37 for immune support" is exactly backwards in SLE, pointing to a harmful role rather than a therapeutic one. Thymosin alpha-1 is the peptide most often discussed here on a Treg-restoration rationale — approved abroad for unrelated conditions, not for SLE, not FDA/EMA-approved, with human lupus data limited to small or uncontrolled reports (no adequate RCT), so investigational at best; Thymalin is a thymic immunomodulator sometimes grouped into autoimmune discussions, but immune-stimulating thymic peptides are cautioned in active autoimmune disease and there is no controlled human evidence for lupus. Lupus is a serious multi-organ disease that demands a licensed clinician and a formal diagnosis; a research peptide is not a substitute, and self-experimentation can be dangerous.

Epstein–Barr virus (EBV) reactivation

Wellness and functional-medicine content claims a "reactivated EBV" can be cleared or suppressed by thymic peptides that reverse "immune exhaustion", positioning thymosin alpha-1 as an antiviral fix for chronic fatigue attributed to EBV. In reality, no peptide is an approved treatment for EBV infection or "EBV reactivation" — there is in fact no antiviral drug approved specifically to treat chronic or reactivated EBV, and "reactivated EBV" as a cause of nonspecific fatigue is itself a contested clinical label requiring proper workup. Thymic peptides have small studies in reactivated herpesvirus infection, but the frequently cited "reverses immune exhaustion" study (PMC7178259) was in human alphaherpesvirus-1 (HSV), not EBV [Human, small/uncontrolled], and there is no controlled human evidence that any inventory peptide treats or prevents EBV reactivation. Thymosin alpha-1 is the main peptide discussed here — approved abroad for hepatitis B and immunodeficiency, not for EBV, with human antiviral data existing for other viruses but no controlled human evidence specifically for EBV; Thymalin is a thymic-extract immunomodulator invoked for "boosting immunity against latent viruses" on under-replicated, general evidence with no controlled human EBV data; Thymogen is a thymalin-derived immune dipeptide sometimes grouped with antiviral "immune support", investigational or anecdotal at best. Persistent EBV-attributed symptoms need a licensed clinician and a proper diagnosis; a research peptide is not a substitute.

Inflammatory bowel disease (Crohn's / ulcerative colitis)

Popular content claims Crohn's and ulcerative colitis can be "healed" or put into remission by gut-repair peptides — most often a BPC-157 + KPV protocol — framed as regenerating the gut lining and switching off inflammation without conventional drugs. In reality, no peptide is an approved treatment for Crohn's disease or ulcerative colitis; IBD is managed by gastroenterologists with approved anti-inflammatory, immunosuppressant, and biologic therapy plus endoscopic monitoring. Notably, BPC-157 did enter real human IBD trials years ago as PL 14736, but no positive randomized controlled trial has ever been published, so despite a large rodent literature it remains without proven human efficacy and has no approved indication [Animal; Human trials unpublished]; KPV is an alpha-MSH-derived tripeptide with genuinely strong preclinical anti-colitis data — it reduced DSS/TNBS colitis in mice via PepT1 uptake and NF-κB blockade (2008 Gastroenterology) — but this is entirely preclinical with zero human trials [Animal/In vitro]; LL-37 is studied in IBD as a marker rather than a marketed therapy, since circulating cathelicidin correlates with mucosal disease activity and stricture risk, which reflects disease biology rather than proven treatment benefit. None has controlled human evidence of efficacy in IBD. Untreated or self-managed IBD carries real risks (strictures, hospitalization); it needs a licensed clinician and a proper diagnosis, and a research peptide is not a substitute for evidence-based IBD care.